Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $27.0052W HIGH $54.85
Volume
1.35 M
Value Traded
32.33 M
Short % Float
23.55%
-3.99%Week
-19.74%1 Month
-29.78%3 Month
-20.86%6 Month
+231.66%5 Year
+281.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.10 B
EPS (TTM)
-0.99
P/E Ratio
-
Ent. Value
1.02 B
Total Shares
37.49 M
Float Shares
31.80 M
Insiders
15.18%
Institutions
57.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
HROW Catalyst Timeline
Dated clinical, regulatory and corporate events for Harrow, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Harrow, Inc.
471Total events
18Upcoming
102Tier-1 (high impact)
2009 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchTYRVAYAPost-Market
TYRVAYA available to eyecare professionals through Harrow's commercial organization immediately after closing
dry eye diseasesource ↗
●Poster PresentationVERKAZIAApprovedPresentation
Poster: Early symptom relief with cyclosporine A 0.1% cationic emulsion in pediatric VKC (descriptive analysis)
Vernal Keratoconjunctivitissource ↗
●Poster PresentationVERKAZIAApprovedPresentation
Poster: Safety of cyclosporine A 0.1% cationic emulsion in VKC, pooled NOVATIVE/VEKTIS with prior-antiallergic subgroup
Vernal Keratoconjunctivitissource ↗
●Poster PresentationVEVYEApprovedPresentation
Poster: 52-week corneal endothelial health trial in dry eye patients treated with cyclosporine ophthalmic solution 0.1%
Dry Eye Diseasesource ↗
●Poster PresentationFLAREXPresentation
Poster: Randomized double-masked comparison of ocular tolerability and patient preference for fluorometholone acetate vs loteprednol etabonate gel
Ocular Inflammationsource ↗
●Poster PresentationPresentation
Poster: Treatment outcomes in chronic blepharitis managed by topical prescription therapies (systematic review and meta-analysis)
Chronic Blepharitissource ↗
▲Full ResultsIHEEZOApprovedClinical Data
Positive results from prospective, randomized, contralateral-eye study of IHEEZO in intravitreal injections
ocular surface anesthesiasource ↗
◆AcquisitionTYRVAYACorporate
Harrow enters definitive agreement to acquire TYRVAYA from Viatris
dry eye diseasesource ↗
◆Oral PresentationIHEEZOApprovedPresentation
Interim findings from investigator-initiated study comparing IHEEZO vs subconjunctival lidocaine presented at ASRS 2026
ocular surface anesthesiasource ↗
◆Oral PresentationBYOOVIZPresentation
Interim findings from real-world post-marketing surveillance study of BYOOVIZ presented at ASRS 2026
neovascular AMD, macular edema following RVO, mCNVsource ↗
◆Enrollment UpdateIHEEZOApprovedTrial
QUELL trial enrollment ongoing
post-injection pain and patient experiencesource ↗
◆Oral PresentationSB11Presentation
Interim data from PMS study on SB11 presented at ASRS 2026
retinal diseasessource ↗
▲Product LaunchBYOOVIZPost-Market
Relaunch of BYOOVIZ (ranibizumab-nuna) in the United States
▲Product LaunchVERKAZIAApprovedPost-Market
Re-launch of VERKAZIA for VKC
vernal keratoconjunctivitissource ↗
◆Oral PresentationPresentation
Harrow to present at William Blair's 46th Annual Growth Stock Conference
▲Product LaunchVEVYEApprovedPost-Market
Doubling of VEVYE sales force on track to be completed by Memorial Day 2026
dry eye diseasesource ↗
▲Other Regulator MilestoneEx-US Regulatory
CMS assigned permanent J-Code J2374 for IOPIDINE 1%
prevention of intraocular pressure spikes following ophthalmic proceduressource ↗
◆AbstractILEVROApprovedPresentation
Abstract accepted for ASCRS 2026: Post-Hoc Analysis of the Effect of Nepafenac 0.3% on Reducing Clinically Significant Visual Acuity Loss Associated with Cataract Surgery in subjects with Macular Edema
post-cataract surgery macular edemasource ↗
◆AbstractVEVYEApprovedPresentation
Abstract accepted for ASCRS 2026: Dual-Function Cyclosporine 0.1% in Perfluorobutylpentane as an Alternative to Corticosteroids in Post-Fungal Keratoplasty
post-fungal keratoplastysource ↗
◆First Patient DosedTRIESENCEApprovedTrial
Enrollment start expected in Q2 2026
ocular inflammation and pain following cataract surgerysource ↗
◆Oral PresentationPresentation
Harrow management to present at Leerink Partners 2026 Global Healthcare Conference
▲IND ClearanceTRIESENCEApprovedIND
FDA cleared IND for TRIESENCE Phase 3 trial in post-cataract surgery inflammation and pain
ocular inflammation and pain following cataract surgerysource ↗
▲Quarterly UpdateVEVYEApprovedCorporate
VEVYE record new and total prescription performance in Q1 2026
dry eye diseasesource ↗
▲Quarterly UpdateIHEEZOApprovedCorporate
IHEEZO unit demand increased 18% year-over-year in Q1 2026
ophthalmicsource ↗
▲Quarterly UpdateTRIESENCEApprovedCorporate
TRIESENCE unit demand more than doubled year-over-year in Q1 2026
ophthalmicsource ↗
◆Quarterly UpdateCorporate
Full year 2025 financial results to be released in early March 2026
▲Product LaunchPharmaPackPost-Market
Launch of PharmaPack cash-pay direct-to-prescriber kits
infection control and treatment of pain and inflammation associated with cataract surgerysource ↗
▲Trial InitiationTrial
Ancillary studies for MELT-300 NDA support initiated (one non-clinical animal study and three PK studies)
not specifiedsource ↗
▲Product LaunchIHEEZOApprovedPost-Market
Expansion of IHEEZO commercial footprint to office-based setting underway
office-based ophthalmic proceduressource ↗
▼License DisputeIP / Competition
ImprimisRx voluntarily forfeited California license and paid fine
▼Other Regulator MilestoneEx-US Regulatory
ImprimisRx settled pending regulatory matters with California Board of Pharmacy and voluntarily exited California market
◆Trial InitiationTRIESENCEApprovedTrial
Phase 3 trial initiation expected in Q1 2026
ocular inflammation and pain following cataract surgerysource ↗
▲Product LaunchTRIESENCEApprovedPost-Market
Doubling of TRIESENCE surgical sales force in coming months
ocular inflammationsource ↗
▲Product LaunchBYOOVIZPost-Market
Harrow to assume full commercial responsibility for BYOOVIZ in the US
Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Myopic Choroidal Neovascularizationsource ↗
Past FDA Catalysts and PDUFA Decisions
How HROW actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | MELT-300 | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$61M
Pipeline Value
$653M
Commercial Value
Overvalued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 48%
Micro Cap(rank 317 of 660)
Percentile Rank
Harrow, Inc. faces pipeline headwinds (37/100), with $153M risk-adjusted pipeline value, led by SURF-201 in Post-surgical Ocular Inflammation (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $275.6M x 2.4 = $653M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VEVYE | $99M | $61M | +61.3% |
| IHEEZO | $75M | $59M | +27.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SURF-201 Small moleculeCompletedNCT04324359 | Post-surgical Ocular Inflammation | Phase 2 | COMPLETED | 91 | Nov 20, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every HROW program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IHEEZO | ocular surface anesthesia | 2026-08-20 | 58% less discomfort; 1.44 versus 3.06 at two minutes; 1.26 versus 2.82 at one hour; 1.62 points at two minutes; 1.56 points at one hourRead More | Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shojaei AmirOfficer (CHIEF SCIENTIFIC OFFICER) | Option | 11,250 11,250 held | $35.96 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HROW
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 9.2 % (-30.3 %) | 101.93 M | 2.40 M | -15.26% ( -432.23 K) |
HROW Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-09-17 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HROW ranks across every disease it competes in
Competitive Position is a premium feature
See how HROW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHROW News
HROWHarrow Closes Acquisition of TYRVAYA®
Harrow has successfully completed the acquisition of TYRVAYA, a nasal spray for dry eye disease, from Viatris. The deal grants Harrow worldwide rights, excluding Japan, and involves an initial payment of $30 million, with potential milestone payments up to $70 million. This acquisition is expected to strengthen Harrow's position in the dry eye market and enhance its product offerings for eyecare professionals.
Read more →HROWHarrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Harrow (Nasdaq: HROW) announced that 15 scientific abstracts from its ophthalmic portfolio will be presented at the American Academy of Optometry and the American Academy of Ophthalmology meetings in 2026. The presentations will cover various conditions including dry eye disease and ocular inflammation, highlighting Phase 3 trial results and long-term safety data. This reflects Harrow's commitment to providing clinically relevant data for healthcare professionals.
Read more →HROWHarrow to Participate in Three Investor Conferences in September
Harrow (Nasdaq: HROW) will participate in three investor conferences in September 2026, including the Cantor Global Healthcare Conference, Lake Street Capital Markets 10th Annual Best Ideas Growth Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The events will feature fireside chats and one-on-one investor meetings, with live webcasts available for two of the conferences. This engagement reflects Harrow's commitment to investor relations.
Read more →HROWHarrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow announced positive results from a study on IHEEZO, an ophthalmic gel, showing it significantly reduces patient discomfort during intravitreal injections. The study demonstrated that patients reported 58% less discomfort with IHEEZO compared to a traditional anesthetic. These findings suggest that IHEEZO may enhance patient experience and confidence among retina specialists.
Read more →HROWHarrow Announces Second Quarter 2026 Financial Results
Harrow reported its financial results for the second quarter of 2026, showcasing a significant revenue increase of 60% compared to the previous quarter and an 11% rise year-over-year. The company reaffirmed its full-year revenue guidance, projecting between $350 million and $365 million, alongside an Adjusted EBITDA forecast of $80 million to $100 million.
Read more →HROWHarrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has announced the acquisition of TYRVAYA, the first FDA-approved nasal spray for dry eye disease, from Viatris. This strategic move enhances Harrow's product portfolio, allowing for a broader range of treatment options for physicians and patients. The acquisition is valued at up to $100 million and is expected to close in the second half of 2026.
Read more →HROWHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow (Nasdaq: HROW) will report its second quarter financial results on August 10, 2026, after market close. A conference call will be held on August 11, 2026, at 8:00 a.m. ET to discuss these results and provide a business update. The financial results will be available on their website along with a Letter to Stockholders.
Read more →HROWSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Samsung Bioepis and Harrow presented interim data from a post-marketing surveillance study on SB11, a biosimilar to Lucentis, at the ASRS 2026 meeting. The study demonstrated a comparable safety profile to ranibizumab and showed significant efficacy improvements in treatment-naïve patients while maintaining efficacy in those switched from other anti-VEGF treatments. The findings support the clinical use of SB11 in retinal disease management.
Read more →HROWHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow presented three studies at the ASRS 2026 Annual Meeting, highlighting the clinical evidence supporting IHEEZO and BYOOVIZ. The studies suggest IHEEZO may reduce post-procedure pain and improve patient experience. Additionally, a large-scale trial, QUELL, is underway to further evaluate IHEEZO's effectiveness. The findings reinforce Harrow's commitment to retina specialists and patient care.
Read more →HROWHarrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow has announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar for treating retinal diseases. This product, developed in partnership with Samsung Bioepis, is the first ophthalmology biosimilar in the U.S. and aims to enhance treatment options for conditions like Neovascular AMD and RVO. The launch reinforces Harrow's position in the retinal biologics market, catering to the needs of retina specialists.
Read more →HROWSamsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Samsung Bioepis has announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States in collaboration with Harrow. This partnership aims to enhance the availability of the biosimilar treatment. Further details regarding the implications of this relaunch were not provided in the article.
Read more →HROW▲ +7.3%on this news
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
Harrow has re-launched VERKAZIA, a cyclosporine ophthalmic emulsion, for treating vernal keratoconjunctivitis (VKC), particularly in children. This product aims to fill a critical gap in pediatric ophthalmic care by providing a steroid-sparing option that targets the underlying inflammation of VKC. The re-launch is supported by a robust commercial strategy to enhance physician education and patient access.
Read more →HROWHarrow to Present at William Blair’s 46th Annual Growth Stock Conference
Harrow (Nasdaq: HROW) will present at William Blair's 46th Annual Growth Stock Conference on June 3, 2026, at 8:40 AM CT in Chicago. The presentation will be available via live webcast on the company's website, with a replay accessible for 90 days. Harrow specializes in ophthalmic disease management solutions.
Read more →HROWHarrow Announces First Quarter 2026 Financial Results First Quarter 2026 and Selected Highlights: VEVYE delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded d
Harrow (HROW) reported its financial results for the first quarter of 2026, highlighting a record performance for its ophthalmic product VEVYE, despite a decline in the branded dry eye market. The company achieved revenues of $44.2 million for the quarter, although this was impacted by an $8 million gross-to-net adjustment. Harrow reaffirmed its full-year revenue guidance, expecting between $350 million and $365 million. Additionally, the company noted substantial growth in unit demand for its other products, IHEEZO and TRIESENCE, and a solid cash position of $94.6 million.
Read more →HROWHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Harrow (Nasdaq: HROW) announced it will report its first quarter 2026 financial results on May 11, 2026, after market close. A conference call and webcast will follow on May 12, 2026, at 8:00 a.m. ET for discussing the results and providing updates. The company emphasizes its dedication to ophthalmic disease management.
Read more →HROWHarrow Announces the Issuance of J-Code for IOPIDINE® 1%
Harrow has announced that IOPIDINE® 1% has been assigned a permanent J-Code (J2374) by CMS, effective July 1, 2026. This designation allows for reimbursement when administered in-office, facilitating its use in glaucoma procedures. The drug is the only FDA-approved solution to prevent intraocular pressure spikes, significantly improving patient care and procedural outcomes.
Read more →HROWLogiCare3PL Selected as Distribution Partner by Harrow
LogiCare3PL has been chosen by Harrow, Inc. as a distribution partner for its ophthalmic disease management solutions, effective February 1, 2026. The partnership aims to enhance market access and ensure business continuity through efficient logistics services. LogiCare3PL's commitment to customer-centricity and rapid execution played a key role in this collaboration.
Read more →HROWHarrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow announced an add-on offering of $50 million in senior unsecured notes due 2030 to support its growth initiatives. The funds will be used for general corporate purposes, including product development and strategic opportunities. The offering is targeted at qualified institutional buyers and is not registered under the Securities Act.
Read more →HROWHarrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Harrow has announced the pricing of a $50 million offering of 8.625% senior unsecured notes due 2030. The offering, which is expected to close on March 27, 2026, will support general corporate purposes, including growth initiatives and product development. The notes will be guaranteed by the company's subsidiaries and will be treated as a single series with previously issued notes.
Read more →HROWHarrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Harrow (Nasdaq: HROW) announced that three abstracts related to its ophthalmic products VEVYE® and ILEVRO® have been accepted for presentation at the ASCRS 2026 Annual Meeting. The research focuses on treatment options for dry eye disease and complications following cataract surgery. The meeting will take place from April 10-13, 2026, in Washington, D.C.
Read more →About Harrow, Inc.
Headquarters1A BURTON HILLS BLVD, NASHVILLE, TN
BIOPHARMAWATCH ELITE PLUS
Trade the next HROW catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime